Kilitch Drugs (India)'s Q2 FY 2025-26 Quarterly Results

Result Summary

• Kilitch Drugs (India) Ltd reported a 21.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.6%.
• Its expenses for the quarter were up by 9.3% QoQ and 9.2% YoY.
• The net profit increased 254.2% QoQ and decreased 6.6% YoY.
• The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 4.97 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Kilitch Drugs (India) Ltd is a pharmaceutical company specializing in the manufacturing and marketing of pharmaceutical products. The company operates primarily within the healthcare sector, focusing on the production of a variety of drugs and formulations. Kilitch Drugs has a significant presence in both domestic and international markets, offering a diverse range of therapeutic products. Although specific recent developments are not provided in the current data, the company's ongoing operations likely involve continuous research and development efforts to expand its product portfolio and enhance production capabilities.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Kilitch Drugs reported a total income of ₹55.58 crores, marking a 21.6% increase compared to the first quarter of fiscal year 2026 (Q1FY26), which was ₹45.70 crores. When compared to the second quarter of fiscal year 2025 (Q2FY25), which recorded total income of ₹52.64 crores, there is a year-over-year growth of 5.6%. This suggests that there has been an upward trend in the company's revenue generation over both the quarterly and annual periods.

Profitability

Kilitch Drugs' profitability in Q2FY26 demonstrated significant improvements on a quarter-over-quarter basis. The profit before tax was ₹9.40 crores, a substantial increase of 172.5% from ₹3.45 crores in Q1FY26. However, this figure shows a decline of 9.2% when compared to the ₹10.35 crores reported in Q2FY25. The profit after tax for Q2FY26 was ₹8.04 crores, reflecting a remarkable 254.2% increase from Q1FY26's ₹2.27 crores, though it experienced a 6.6% decrease compared to Q2FY25's ₹8.61 crores. Earnings per share (EPS) also increased to ₹4.97 in Q2FY26 from ₹1.88 in Q1FY26, a rise of 164.4%, but decreased by 7.3% from ₹5.36 in Q2FY25.

Operating Metrics

The total expenses for Kilitch Drugs in Q2FY26 were reported at ₹46.18 crores, which represents a 9.3% increase from ₹42.25 crores in Q1FY26 and a 9.2% increase from ₹42.29 crores in Q2FY25. The tax expense in Q2FY26 was ₹1.36 crores, up by 14.3% from the ₹1.19 crores in Q1FY26, but down by 21.4% from the ₹1.73 crores in Q2FY25. These figures indicate changes in the company's cost structure and tax liabilities over the periods in question. The financial data reflects a significant variation in the operational costs and tax management strategies employed by Kilitch Drugs during the analyzed quarters.